AAVB 081
Alternative Names: AAV8.MYO7A; AAVB-081Latest Information Update: 20 May 2025
At a glance
- Originator AAVantgarde Bio
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Myosin VIIa replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Usher syndrome type 1B
Most Recent Events
- 12 May 2025 Updated adverse events and efficacy data from the phase I/II trial in Usher syndrome type 1B released by AAVantgarde Bio
- 09 Dec 2024 Adverse events data from a phase I/II trial in Usher syndrome type 1B released by AAVantgarde Bio
- 02 Dec 2024 AAVB 081 receives Orphan Drug status for Usher syndrome type 1B in USA